Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468236 | 0.83 | SSTR4 (0.46) | SCN9AKCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL12776096 | 0.81 | SLC13A5 (0.48) | SCN2ASCN10ASSTR4RIPK1 | |
| SCHEMBL18014775 | 0.81 | MAOB (0.46) | — | |
| SCHEMBL3287500 | 0.80 | SCN9A (0.42) | SCN9AKCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL30931696 | 0.80 | SCN9A (0.42) | SCN9AKCNH2SCN5ASCN2ASCN10A | |
| SCHEMBL12776098 | 0.80 | SLC13A5 (0.47) | RIPK1 | |
| SCHEMBL6371918 | 0.77 | SSTR4 (0.45) | SCN9ASSTR4SSTR1 | |
| SCHEMBL13424282 | 0.76 | SSTR4 (0.45) | SCN9AHCRTR1HCRTR2SSTR4GPBAR1 | |
| SCHEMBL18014793 | 0.76 | IDO1 (0.47) | KCNH2 | |
| SCHEMBL18726968 | 0.75 | SCN9A (0.43) | SCN9AKCNH2SCN5ASCN2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | SCN9A 19/4885KCNH2 40/4885SCN5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.